A two-way crossover clinical trial to investigate the pharmacokinetics and oral bioavailability and to assess the safety and tolerability of RPL554

Trial Profile

A two-way crossover clinical trial to investigate the pharmacokinetics and oral bioavailability and to assess the safety and tolerability of RPL554

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs RPL 554 (Primary)
  • Indications Chronic obstructive pulmonary disease; Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 27 Sep 2017 Top-line data presented in a Verona Pharma Media Release.
    • 08 Aug 2017 According to a Verona Pharma media release, dosing in this study is completed and top-line data is expected in the fourth quarter of 2017.
    • 05 Jun 2017 According to a Verona Pharma media release, first patient has been enrolled in the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top